<?xml version="1.0" encoding="UTF-8"?>
<drug type="biotech" created="2007-11-18" updated="2019-12-02">
  <drugbank-id primary="true">DB05829</drugbank-id>
  <name>Parathyroid hormone</name>
  <description>Parathyroid hormone (PTH)  is a single-chain polypeptide composed of 84 amino acids.  Available as Preotact, it is an identical form of human recombinant hormome which produced as a fusion protein undergoeing post-translational processing involving the cleavage of the OmpA leader sequence, leaving the mature protein as a single-chain 84 amino-acids polypeptide (9.4 kDa).&#13;
&#13;
Preotact is used in the treatment of osteoporosis in postmenopausal women at high risk of osteoporotic fractures and is marketed in Europe by Nycomed. Preos is a registered trade mark owned by NPS Pharmaceuticals, Inc. The name Preos and the New Drug Application is pending approval by the U.S. Food and Drug Administration (FDA).</description>
  <cas-number>9002-64-6</cas-number>
  <unii>N19A0T0E5J</unii>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A3830</ref-id>
        <pubmed-id>17590097</pubmed-id>
        <citation>Sosa Henriquez M, Diez Perez A: [Parathyroid hormone in the treatment of osteoporosis]. An Med Interna. 2007 Feb;24(2):87-97.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference>Robert L. Colescott, Geoffrey W. Tregear, "Synthesis of peptides with parathyroid hormone activity." U.S. Patent US4105602, issued May, 1977.</synthesis-reference>
  <indication>For use/treatment in osteoporosis.</indication>
  <pharmacodynamics>Parathyroid hormone is responsible for the fine regulation of serum calcium concentration on a minute-to-minute basis. This is achieved by the acute effects of the hormone on calcium resorption in bone and calcium reabsorption in the kidney. The phosphate mobilized from bone is excreted into the urine by means of the hormone's influence on renal phosphate handling. Parathyroid hormone also stimulates calcium absorption in the intestine, this being mediated indirectly by 1,25-dihydroxyvitamin D. Thus, a hypocalcemic stimulus of parathyroid hormone secretion results in an increased influx of calcium from three sources (bone, kidney, and intestine), resulting in a normalization of the serum calcium concentration without change in the serum phosphate concentration.</pharmacodynamics>
  <mechanism-of-action>The biological actions of rhPTH are mediated through binding to at least two distinct high- affinity cell-surface receptors specific for the N-terminal and C-terminal regions of the molecule, both of which are required for normal bone metabolism. The N-terminal portion of the molecule is primarily responsible for the bone building effects of parathyroid hormone. The C-terminal portion of the molecule has antiresorptive activity and is necessary for normal regulation of N-terminal fragment activity.</mechanism-of-action>
  <toxicity/>
  <metabolism>PTH is primarily metabolised in the liver with lesser contributions by the kidney. Amino terminal fragments are metabolised in the liver while carboxyl terminal groups travel to the kidney for metabolism where they are also thought to have a role in regulation of PTH. Only about 30% of circulating hormone is present as the unfragmented form.</metabolism>
  <absorption>The absolute bioavailability after subcutaneous administration in the abdomen is 55% for doses of 100 micrograms.</absorption>
  <half-life>1.5 hours.</half-life>
  <protein-binding/>
  <route-of-elimination>Carboxy-terminal fragments are filtered by the kidney and subsequently broken down into even smaller fragments during tubular reuptake.</route-of-elimination>
  <volume-of-distribution>The volume of distribution at steady-state following intravenous administration is approximately 5.4 liters with an interpatient variability of about 40%.</volume-of-distribution>
  <clearance/>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">Parathormone</synonym>
    <synonym language="english" coder="">Parathormone (human recombinant)</synonym>
    <synonym language="english" coder="">Parathyrin</synonym>
    <synonym language="english" coder="">Parathyroid hormone</synonym>
    <synonym language="english" coder="">Parathyroid hormone (1-84) human recombinant</synonym>
    <synonym language="english" coder="">Parathyroid hormone (rDNA)</synonym>
    <synonym language="english" coder="">PTH</synonym>
    <synonym language="english" coder="">PTH(1-84)</synonym>
    <synonym language="english" coder="">rhPTH</synonym>
    <synonym language="english" coder="">rhPTH(1-84)</synonym>
    <synonym language="english" coder="">rPTH</synonym>
    <synonym language="english" coder="">rPTH(1-84)</synonym>
  </synonyms>
  <products>
    <product>
      <name>NATPARA (parathyroid hormone)</name>
      <labeller>Shire-NPS Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68875-0202</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-01-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>25 ug/0.08mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA125511</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>NATPARA (parathyroid hormone)</name>
      <labeller>Shire-NPS Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68875-0203</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-01-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>50 ug/0.08mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA125511</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>NATPARA (parathyroid hormone)</name>
      <labeller>Shire-NPS Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68875-0204</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-01-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>75 ug/0.08mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA125511</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>NATPARA (parathyroid hormone)</name>
      <labeller>Shire-NPS Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68875-0205</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-01-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>100 ug/0.08mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA125511</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Preotact</name>
      <labeller>Nps Pharma Holdings Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000659</ema-product-code>
      <ema-ma-number>EU/1/06/339/003</ema-ma-number>
      <started-marketing-on>2006-04-24</started-marketing-on>
      <ended-marketing-on>2014-07-11</ended-marketing-on>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>100 µg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Preos</name>
      <company>NPS Pharmaceuticals, Inc.</company>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Preotact</name>
      <ingredients>Parathyroid hormone</ingredients>
    </mixture>
    <mixture>
      <name>NATPARA (parathyroid hormone)</name>
      <ingredients>Parathyroid hormone</ingredients>
    </mixture>
    <mixture>
      <name>NATPARA (parathyroid hormone)</name>
      <ingredients>Parathyroid hormone</ingredients>
    </mixture>
    <mixture>
      <name>NATPARA (parathyroid hormone)</name>
      <ingredients>Parathyroid hormone</ingredients>
    </mixture>
    <mixture>
      <name>NATPARA (parathyroid hormone)</name>
      <ingredients>Parathyroid hormone</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Calcium Homeostasis</category>
      <mesh-id/>
    </category>
    <category>
      <category>Calcium-Regulating Hormones and Agents</category>
      <mesh-id>D000077264</mesh-id>
    </category>
    <category>
      <category>Hormones</category>
      <mesh-id>D006728</mesh-id>
    </category>
    <category>
      <category>Hormones, Hormone Substitutes, and Hormone Antagonists</category>
      <mesh-id>D006730</mesh-id>
    </category>
    <category>
      <category>Parathyroid Hormones and Analogues</category>
      <mesh-id/>
    </category>
    <category>
      <category>Peptide Hormones</category>
      <mesh-id>D036361</mesh-id>
    </category>
    <category>
      <category>Peptides</category>
      <mesh-id>D010455</mesh-id>
    </category>
    <category>
      <category>Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins</category>
      <mesh-id/>
    </category>
    <category>
      <category>Thyroid Products</category>
      <mesh-id>D013972</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Subcutaneous</route>
      <strength>100 ug/0.08mL</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Subcutaneous</route>
      <strength>25 ug/0.08mL</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Subcutaneous</route>
      <strength>50 ug/0.08mL</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Subcutaneous</route>
      <strength>75 ug/0.08mL</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Subcutaneous</route>
      <strength>100 µg</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="H05AA03">
      <level code="H05AA">Parathyroid hormones and analogues</level>
      <level code="H05A">PARATHYROID HORMONES AND ANALOGUES</level>
      <level code="H05">CALCIUM HOMEOSTASIS</level>
      <level code="H">SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00390</drugbank-id>
      <name>Digoxin</name>
      <description>The risk or severity of adverse effects can be increased when Parathyroid hormone is combined with Digoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00511</drugbank-id>
      <name>Acetyldigitoxin</name>
      <description>The risk or severity of adverse effects can be increased when Parathyroid hormone is combined with Acetyldigitoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01078</drugbank-id>
      <name>Deslanoside</name>
      <description>The risk or severity of adverse effects can be increased when Parathyroid hormone is combined with Deslanoside.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01092</drugbank-id>
      <name>Ouabain</name>
      <description>The risk or severity of adverse effects can be increased when Parathyroid hormone is combined with Ouabain.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01396</drugbank-id>
      <name>Digitoxin</name>
      <description>The risk or severity of adverse effects can be increased when Parathyroid hormone is combined with Digitoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12843</drugbank-id>
      <name>Oleandrin</name>
      <description>The risk or severity of adverse effects can be increased when Parathyroid hormone is combined with Oleandrin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13240</drugbank-id>
      <name>Cymarin</name>
      <description>The risk or severity of adverse effects can be increased when Parathyroid hormone is combined with Cymarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13307</drugbank-id>
      <name>Proscillaridin</name>
      <description>The risk or severity of adverse effects can be increased when Parathyroid hormone is combined with Proscillaridin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13401</drugbank-id>
      <name>Metildigoxin</name>
      <description>The risk or severity of adverse effects can be increased when Parathyroid hormone is combined with Metildigoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13467</drugbank-id>
      <name>Lanatoside C</name>
      <description>The risk or severity of adverse effects can be increased when Parathyroid hormone is combined with Lanatoside C.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13537</drugbank-id>
      <name>Gitoformate</name>
      <description>The risk or severity of adverse effects can be increased when Parathyroid hormone is combined with Gitoformate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13691</drugbank-id>
      <name>Acetyldigoxin</name>
      <description>The risk or severity of adverse effects can be increased when Parathyroid hormone is combined with Acetyldigoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13756</drugbank-id>
      <name>Peruvoside</name>
      <description>The risk or severity of adverse effects can be increased when Parathyroid hormone is combined with Peruvoside.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00176</drugbank-id>
      <name>Fluvoxamine</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Fluvoxamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00215</drugbank-id>
      <name>Citalopram</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00472</drugbank-id>
      <name>Fluoxetine</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Fluoxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00476</drugbank-id>
      <name>Duloxetine</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Duloxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00656</drugbank-id>
      <name>Trazodone</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Trazodone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00715</drugbank-id>
      <name>Paroxetine</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Paroxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01104</drugbank-id>
      <name>Sertraline</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Sertraline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01105</drugbank-id>
      <name>Sibutramine</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Sibutramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01149</drugbank-id>
      <name>Nefazodone</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Nefazodone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01175</drugbank-id>
      <name>Escitalopram</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Escitalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04832</drugbank-id>
      <name>Zimelidine</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Zimelidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04884</drugbank-id>
      <name>Dapoxetine</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Dapoxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04896</drugbank-id>
      <name>Milnacipran</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Milnacipran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06700</drugbank-id>
      <name>Desvenlafaxine</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Desvenlafaxine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06731</drugbank-id>
      <name>Seproxetine</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Seproxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08918</drugbank-id>
      <name>Levomilnacipran</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Levomilnacipran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08953</drugbank-id>
      <name>Indalpine</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Indalpine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12693</drugbank-id>
      <name>Ritanserin</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Ritanserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13233</drugbank-id>
      <name>Alaproclate</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Alaproclate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00282</drugbank-id>
      <name>Pamidronic acid</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Pamidronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00399</drugbank-id>
      <name>Zoledronic acid</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Zoledronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00630</drugbank-id>
      <name>Alendronic acid</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00710</drugbank-id>
      <name>Ibandronate</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Ibandronate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00720</drugbank-id>
      <name>Clodronic acid</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Clodronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00884</drugbank-id>
      <name>Risedronic acid</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Risedronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01077</drugbank-id>
      <name>Etidronic acid</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Etidronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01133</drugbank-id>
      <name>Tiludronic acid</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Tiludronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06255</drugbank-id>
      <name>Incadronic acid</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Incadronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00182</drugbank-id>
      <name>Amphetamine</name>
      <description>The risk or severity of adverse effects can be increased when Amphetamine is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00191</drugbank-id>
      <name>Phentermine</name>
      <description>The risk or severity of adverse effects can be increased when Phentermine is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00211</drugbank-id>
      <name>Midodrine</name>
      <description>The risk or severity of adverse effects can be increased when Midodrine is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00368</drugbank-id>
      <name>Norepinephrine</name>
      <description>The risk or severity of adverse effects can be increased when Norepinephrine is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00388</drugbank-id>
      <name>Phenylephrine</name>
      <description>The risk or severity of adverse effects can be increased when Phenylephrine is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00397</drugbank-id>
      <name>Phenylpropanolamine</name>
      <description>The risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00610</drugbank-id>
      <name>Metaraminol</name>
      <description>The risk or severity of adverse effects can be increased when Metaraminol is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00668</drugbank-id>
      <name>Epinephrine</name>
      <description>The risk or severity of adverse effects can be increased when Epinephrine is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00723</drugbank-id>
      <name>Methoxamine</name>
      <description>The risk or severity of adverse effects can be increased when Methoxamine is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00816</drugbank-id>
      <name>Orciprenaline</name>
      <description>The risk or severity of adverse effects can be increased when Orciprenaline is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00830</drugbank-id>
      <name>Phenmetrazine</name>
      <description>The risk or severity of adverse effects can be increased when Phenmetrazine is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00841</drugbank-id>
      <name>Dobutamine</name>
      <description>The risk or severity of adverse effects can be increased when Dobutamine is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00852</drugbank-id>
      <name>Pseudoephedrine</name>
      <description>The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00865</drugbank-id>
      <name>Benzphetamine</name>
      <description>The risk or severity of adverse effects can be increased when Benzphetamine is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00867</drugbank-id>
      <name>Ritodrine</name>
      <description>The risk or severity of adverse effects can be increased when Ritodrine is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00871</drugbank-id>
      <name>Terbutaline</name>
      <description>The risk or severity of adverse effects can be increased when Terbutaline is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00935</drugbank-id>
      <name>Oxymetazoline</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00937</drugbank-id>
      <name>Diethylpropion</name>
      <description>The risk or severity of adverse effects can be increased when Diethylpropion is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00988</drugbank-id>
      <name>Dopamine</name>
      <description>The risk or severity of adverse effects can be increased when Dopamine is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01064</drugbank-id>
      <name>Isoprenaline</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01255</drugbank-id>
      <name>Lisdexamfetamine</name>
      <description>The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01288</drugbank-id>
      <name>Fenoterol</name>
      <description>The risk or severity of adverse effects can be increased when Fenoterol is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01364</drugbank-id>
      <name>Ephedrine</name>
      <description>The risk or severity of adverse effects can be increased when Ephedrine is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01365</drugbank-id>
      <name>Mephentermine</name>
      <description>The risk or severity of adverse effects can be increased when Mephentermine is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01366</drugbank-id>
      <name>Procaterol</name>
      <description>The risk or severity of adverse effects can be increased when Procaterol is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01407</drugbank-id>
      <name>Clenbuterol</name>
      <description>The risk or severity of adverse effects can be increased when Clenbuterol is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01442</drugbank-id>
      <name>MMDA</name>
      <description>The risk or severity of adverse effects can be increased when MMDA is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01454</drugbank-id>
      <name>Midomafetamine</name>
      <description>The risk or severity of adverse effects can be increased when Midomafetamine is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01467</drugbank-id>
      <name>2,5-Dimethoxy-4-ethylamphetamine</name>
      <description>The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01484</drugbank-id>
      <name>4-Bromo-2,5-dimethoxyamphetamine</name>
      <description>The risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01509</drugbank-id>
      <name>Tenamfetamine</name>
      <description>The risk or severity of adverse effects can be increased when Tenamfetamine is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01556</drugbank-id>
      <name>Chlorphentermine</name>
      <description>The risk or severity of adverse effects can be increased when Chlorphentermine is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01566</drugbank-id>
      <name>Methylenedioxyethamphetamine</name>
      <description>The risk or severity of adverse effects can be increased when Methylenedioxyethamphetamine is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01576</drugbank-id>
      <name>Dextroamphetamine</name>
      <description>The risk or severity of adverse effects can be increased when Dextroamphetamine is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01577</drugbank-id>
      <name>Metamfetamine</name>
      <description>The risk or severity of adverse effects can be increased when Metamfetamine is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06152</drugbank-id>
      <name>Nylidrin</name>
      <description>The risk or severity of adverse effects can be increased when Nylidrin is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06764</drugbank-id>
      <name>Tetryzoline</name>
      <description>The risk or severity of adverse effects can be increased when Tetryzoline is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08841</drugbank-id>
      <name>Tyramine</name>
      <description>The risk or severity of adverse effects can be increased when Tyramine is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08941</drugbank-id>
      <name>Isoxsuprine</name>
      <description>The risk or severity of adverse effects can be increased when Isoxsuprine is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08985</drugbank-id>
      <name>Etilefrine</name>
      <description>The risk or severity of adverse effects can be increased when Etilefrine is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09203</drugbank-id>
      <name>Synephrine</name>
      <description>The risk or severity of adverse effects can be increased when Synephrine is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09480</drugbank-id>
      <name>Iofetamine I-123</name>
      <description>The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11124</drugbank-id>
      <name>Racepinephrine</name>
      <description>The risk or severity of adverse effects can be increased when Racepinephrine is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12080</drugbank-id>
      <name>Ritobegron</name>
      <description>The risk or severity of adverse effects can be increased when Ritobegron is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13064</drugbank-id>
      <name>Tramazoline</name>
      <description>The risk or severity of adverse effects can be increased when Tramazoline is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13108</drugbank-id>
      <name>Mephedrone</name>
      <description>The risk or severity of adverse effects can be increased when Mephedrone is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13341</drugbank-id>
      <name>Fenozolone</name>
      <description>The risk or severity of adverse effects can be increased when Fenozolone is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13624</drugbank-id>
      <name>Methoxyphenamine</name>
      <description>The risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13692</drugbank-id>
      <name>Tretoquinol</name>
      <description>The risk or severity of adverse effects can be increased when Tretoquinol is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13703</drugbank-id>
      <name>Gepefrine</name>
      <description>The risk or severity of adverse effects can be increased when Gepefrine is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13777</drugbank-id>
      <name>Prenalterol</name>
      <description>The risk or severity of adverse effects can be increased when Prenalterol is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13852</drugbank-id>
      <name>Mefenorex</name>
      <description>The risk or severity of adverse effects can be increased when Mefenorex is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13940</drugbank-id>
      <name>2,5-Dimethoxy-4-ethylthioamphetamine</name>
      <description>The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00598</drugbank-id>
      <name>Labetalol</name>
      <description>The risk or severity of adverse effects can be increased when Labetalol is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01193</drugbank-id>
      <name>Acebutolol</name>
      <description>The risk or severity of adverse effects can be increased when Acebutolol is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04846</drugbank-id>
      <name>Celiprolol</name>
      <description>The risk or severity of adverse effects can be increased when Celiprolol is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12752</drugbank-id>
      <name>Bucindolol</name>
      <description>The risk or severity of adverse effects can be increased when Bucindolol is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13757</drugbank-id>
      <name>Epanolol</name>
      <description>The risk or severity of adverse effects can be increased when Epanolol is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00317</drugbank-id>
      <name>Gefitinib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Gefitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00398</drugbank-id>
      <name>Sorafenib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Sorafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00530</drugbank-id>
      <name>Erlotinib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Erlotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00619</drugbank-id>
      <name>Imatinib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Imatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01254</drugbank-id>
      <name>Dasatinib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Dasatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01259</drugbank-id>
      <name>Lapatinib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Lapatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01268</drugbank-id>
      <name>Sunitinib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Sunitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01645</drugbank-id>
      <name>Genistein</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Genistein.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02058</drugbank-id>
      <name>3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02424</drugbank-id>
      <name>Geldanamycin</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Geldanamycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02567</drugbank-id>
      <name>PD173955</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with PD173955.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03758</drugbank-id>
      <name>Radicicol</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Radicicol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04849</drugbank-id>
      <name>Cediranib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Cediranib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04868</drugbank-id>
      <name>Nilotinib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Nilotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04879</drugbank-id>
      <name>Vatalanib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Vatalanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05294</drugbank-id>
      <name>Vandetanib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Vandetanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05424</drugbank-id>
      <name>Canertinib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Canertinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05465</drugbank-id>
      <name>Tandutinib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Tandutinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05575</drugbank-id>
      <name>Motesanib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Motesanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05928</drugbank-id>
      <name>Dovitinib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Dovitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06302</drugbank-id>
      <name>Glesatinib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Glesatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06469</drugbank-id>
      <name>Lestaurtinib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Lestaurtinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06589</drugbank-id>
      <name>Pazopanib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Pazopanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06595</drugbank-id>
      <name>Midostaurin</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Midostaurin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06616</drugbank-id>
      <name>Bosutinib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Bosutinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06626</drugbank-id>
      <name>Axitinib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Axitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08399</drugbank-id>
      <name>PICEATANNOL</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with PICEATANNOL.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08865</drugbank-id>
      <name>Crizotinib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Crizotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08875</drugbank-id>
      <name>Cabozantinib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Cabozantinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08877</drugbank-id>
      <name>Ruxolitinib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Ruxolitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08881</drugbank-id>
      <name>Vemurafenib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Vemurafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08896</drugbank-id>
      <name>Regorafenib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Regorafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08901</drugbank-id>
      <name>Ponatinib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Ponatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08916</drugbank-id>
      <name>Afatinib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Afatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09053</drugbank-id>
      <name>Ibrutinib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Ibrutinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09063</drugbank-id>
      <name>Ceritinib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Ceritinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09078</drugbank-id>
      <name>Lenvatinib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Lenvatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09079</drugbank-id>
      <name>Nintedanib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Nintedanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09330</drugbank-id>
      <name>Osimertinib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Osimertinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11363</drugbank-id>
      <name>Alectinib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Alectinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11689</drugbank-id>
      <name>Selumetinib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Selumetinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11697</drugbank-id>
      <name>Pacritinib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Pacritinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11703</drugbank-id>
      <name>Acalabrutinib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Acalabrutinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11737</drugbank-id>
      <name>Icotinib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Icotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11805</drugbank-id>
      <name>Saracatinib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Saracatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11828</drugbank-id>
      <name>Neratinib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Neratinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11832</drugbank-id>
      <name>Crenolanib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Crenolanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11904</drugbank-id>
      <name>Flumatinib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Flumatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11963</drugbank-id>
      <name>Dacomitinib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Dacomitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11973</drugbank-id>
      <name>Tesevatinib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Tesevatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11986</drugbank-id>
      <name>Entrectinib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Entrectinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12010</drugbank-id>
      <name>Fostamatinib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Fostamatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12048</drugbank-id>
      <name>Savolitinib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Savolitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12141</drugbank-id>
      <name>Gilteritinib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Gilteritinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12147</drugbank-id>
      <name>Erdafitinib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Erdafitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12267</drugbank-id>
      <name>Brigatinib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Brigatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12307</drugbank-id>
      <name>Foretinib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Foretinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12323</drugbank-id>
      <name>Radotinib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Radotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14723</drugbank-id>
      <name>Larotrectinib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Larotrectinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12978</drugbank-id>
      <name>Pexidartinib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Pexidartinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12500</drugbank-id>
      <name>Fedratinib</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Fedratinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05258</drugbank-id>
      <name>Interferon alfa</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Interferon alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00041</drugbank-id>
      <name>Aldesleukin</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00227</drugbank-id>
      <name>Lovastatin</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Lovastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00609</drugbank-id>
      <name>Ethionamide</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Ethionamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00829</drugbank-id>
      <name>Diazepam</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Diazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00850</drugbank-id>
      <name>Perphenazine</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Perphenazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01233</drugbank-id>
      <name>Metoclopramide</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Metoclopramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14651</drugbank-id>
      <name>Perphenazine enanthate</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Perphenazine enanthate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00233</drugbank-id>
      <name>Aminosalicylic acid</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11085</drugbank-id>
      <name>Resorcinol</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Resorcinol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00222</drugbank-id>
      <name>Glimepiride</name>
      <description>The therapeutic efficacy of Glimepiride can be decreased when used in combination with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00414</drugbank-id>
      <name>Acetohexamide</name>
      <description>The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00672</drugbank-id>
      <name>Chlorpropamide</name>
      <description>The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00839</drugbank-id>
      <name>Tolazamide</name>
      <description>The therapeutic efficacy of Tolazamide can be decreased when used in combination with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01016</drugbank-id>
      <name>Glyburide</name>
      <description>The therapeutic efficacy of Glyburide can be decreased when used in combination with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01067</drugbank-id>
      <name>Glipizide</name>
      <description>The therapeutic efficacy of Glipizide can be decreased when used in combination with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01120</drugbank-id>
      <name>Gliclazide</name>
      <description>The therapeutic efficacy of Gliclazide can be decreased when used in combination with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01124</drugbank-id>
      <name>Tolbutamide</name>
      <description>The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01251</drugbank-id>
      <name>Gliquidone</name>
      <description>The therapeutic efficacy of Gliquidone can be decreased when used in combination with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01289</drugbank-id>
      <name>Glisoxepide</name>
      <description>The therapeutic efficacy of Glisoxepide can be decreased when used in combination with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08962</drugbank-id>
      <name>Glibornuride</name>
      <description>The therapeutic efficacy of Glibornuride can be decreased when used in combination with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13406</drugbank-id>
      <name>Carbutamide</name>
      <description>The therapeutic efficacy of Carbutamide can be decreased when used in combination with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13675</drugbank-id>
      <name>Metahexamide</name>
      <description>The therapeutic efficacy of Metahexamide can be decreased when used in combination with Parathyroid hormone.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences>
    <sequence format="FASTA">&gt;Parathyroid hormone
SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKEDNVLV
ESHEKSLGEADKADVNVLTKAKSQ</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Molecular Weight</kind>
      <value>9420.0</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C408H674N126O126S2</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>5252</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347910255</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C16051</identifier>
    </external-identifier>
    <external-identifier>
      <resource>UniProtKB</resource>
      <identifier>P01270</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Preotact</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0003508</id>
      <name>Parathyroid hormone/parathyroid hormone-related peptide receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>activator</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A17588</ref-id>
            <pubmed-id>10837469</pubmed-id>
            <citation>Jin L, Briggs SL, Chandrasekhar S, Chirgadze NY, Clawson DK, Schevitz RW, Smiley DL, Tashjian AH, Zhang F: Crystal structure of human parathyroid hormone 1-34 at 0.9-A resolution. J Biol Chem. 2000 Sep 1;275(35):27238-44.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q03431" source="Swiss-Prot">
        <name>Parathyroid hormone/parathyroid hormone-related peptide receptor</name>
        <general-function>Protein self-association</general-function>
        <specific-function>This is a receptor for parathyroid hormone and for parathyroid hormone-related peptide. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase and also a phosphatidylinositol-calcium second messenger system.</specific-function>
        <gene-name>PTH1R</gene-name>
        <locus/>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>189-212
220-239
283-306
321-342
362-382
410-428
441-463</transmembrane-regions>
        <signal-regions>1-26</signal-regions>
        <theoretical-pi>8.05</theoretical-pi>
        <molecular-weight>66359.98</molecular-weight>
        <chromosome-location>3</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:9608</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>PTHR1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>BC112247</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>331</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>331</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q03431</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PTH1R_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Parathyroid hormone 1 receptor</synonym>
          <synonym>PTH/PTHr receptor</synonym>
          <synonym>PTH/PTHrP type I receptor</synonym>
          <synonym>PTH1 receptor</synonym>
          <synonym>PTHR</synonym>
          <synonym>PTHR1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0017123|Parathyroid hormone/parathyroid hormone-related peptide receptor
MGTARIAPGLALLLCCPVLSSAYALVDADDVMTKEEQIFLLHRAQAQCEKRLKEVLQRPA
SIMESDKGWTSASTSGKPRKDKASGKLYPESEEDKEAPTGSRYRGRPCLPEWDHILCWPL
GAPGEVVAVPCPDYIYDFNHKGHAYRRCDRNGSWELVPGHNRTWANYSECVKFLTNETRE
REVFDRLGMIYTVGYSVSLASLTVAVLILAYFRRLHCTRNYIHMHLFLSFMLRAVSIFVK
DAVLYSGATLDEAERLTEEELRAIAQAPPPPATAAAGYAGCRVAVTFFLYFLATNYYWIL
VEGLYLHSLIFMAFFSEKKYLWGFTVFGWGLPAVFVAVWVSVRATLANTGCWDLSSGNKK
WIIQVPILASIVLNFILFINIVRVLATKLRETNAGRCDTRQQYRKLLKSTLVLMPLFGVH
YIVFMATPYTEVSGTLWQVQMHYEMLFNSFQGFFVAIIYCFCNGEVQAEIKKSWSRWTLA
LDFKRKARSGSSSYSYGPMVSHTSVTNVGPRVGLGLPLSPRLLPTATTNGHPQLPGHAKP
GTPALETLETTPPAMAAPKDDGFLNGSCSGLDEEASGPERPPALLQEEWETVM</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0017124|Parathyroid hormone/parathyroid hormone-related peptide receptor (PTH1R)
ATGGGGACCGCCCGGATCGCACCCGGCCTGGCGCTCCTGCTCTGCTGCCCCGTGCTCAGC
TCCGCGTACGCGCTGGTGGATGCAGATGACGTCATGACTAAAGAGGAACAGATCTTCCTG
CTGCACCGTGCTCAGGCCCAGTGCGAAAAACGGCTCAAGGAGGTCCTGCAGAGGCCAGCC
AGCATAATGGAATCAGACAAGGGATGGACATCTGCGTCCACATCAGGGAAGCCCAGGAAA
GATAAGGCATCTGGGAAGCTCTACCCTGAGTCTGAGGAGGACAAGGAGGCACCCACTGGC
AGCAGGTACCGAGGGCGCCCCTGTCTGCCGGAATGGGACCACATCCTGTGCTGGCCGCTG
GGGGCACCAGGTGAGGTGGTGGCTGTGCCCTGTCCGGACTACATTTATGACTTCAATCAC
AAAGGCCATGCCTACCGACGCTGTGACCGCAATGGCAGCTGGGAGCTGGTGCCTGGGCAC
AACAGGACGTGGGCCAACTACAGCGAGTGTGTCAAATTTCTCACCAATGAGACTCGTGAA
CGGGAGGTGTTTGACCGCCTGGGCATGATTTACACCGTGGGCTACTCCGTGTCCCTGGCG
TCCCTCACCGTAGCTGTGCTCATCCTGGCCTACTTTAGGCGGCTGCACTGCACGCGCAAC
TACATCCACATGCACCTGTTCCTGTCCTTCATGCTGCGCGCCGTGAGCATCTTCGTCAAG
GACGCTGTGCTCTACTCTGGCGCCACGCTTGATGAGGCTGAGCGCCTCACCGAGGAGGAG
CTGCGCGCCATCGCCCAGGCGCCCCCGCCGCCTGCCACCGCCGCTGCCGGCTACGCGGGC
TGCAGGGTGGCTGTGACCTTCTTCCTTTACTTCCTGGCCACCAACTACTACTGGATTCTG
GTGGAGGGGCTGTACCTGCACAGCCTCATCTTCATGGCCTTCTTCTCAGAGAAGAAGTAC
CTGTGGGGCTTCACAGTCTTCGGCTGGGGTCTGCCCGCTGTCTTCGTGGCTGTGTGGGTC
AGTGTCAGAGCTACCCTGGCCAACACCGGGTGCTGGGACTTGAGCTCCGGGAACAAAAAG
TGGATCATCCAGGTGCCCATCCTGGCCTCCATTGTGCTCAACTTCATCCTCTTCATCAAT
ATCGTCCGGGTGCTCGCCACCAAGCTGCGGGAGACCAACGCCGGCCGGTGTGACACACGG
CAGCAGTACCGGAAGCTGCTCAAATCCACGCTGGTGCTCATGCCCCTCTTTGGCGTCCAC
TACATTGTCTTCATGGCCACACCATACACCGAGGTCTCAGGGACGCTCTGGCAAGTCCAG
ATGCACTATGAGATGCTCTTCAACTCCTTCCAGGGATTTTTTGTCGCAATCATATACTGT
TTCTGCAATGGCGAGGTACAAGCTGAGATCAAGAAATCTTGGAGCCGCTGGACACTGGCA
CTGGACTTCAAGCGAAAGGCACGCAGCGGGAGCAGCAGCTATAGCTACGGCCCCATGGTG
TCCCACACAAGTGTGACCAATGTCGGCCCCCGTGTGGGACTCGGCCTGCCCCTCAGCCCC
CGCCTACTGCCCACTGCCACCACCAACGGCCACCCTCAGCTGCCTGGCCATGCCAAGCCA
GGGACCCCAGCCCTGGAGACCCTCGAGACCACACCACCTGCCATGGCTGCTCCCAAGGAC
GATGGGTTCCTCAACGGCTCCTGCTCAGGCCTGGACGAGGAGGCCTCTGGGCCTGAGCGG
CCACCTGCCCTGCTACAGGAAGAGTGGGAGACAGTCATGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00002</identifier>
            <name>7tm_2</name>
          </pfam>
          <pfam>
            <identifier>PF02793</identifier>
            <name>HRM</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>apical plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>basolateral plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>brush border membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>parathyroid hormone receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>peptide hormone binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein self-association</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-activating G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-modulating G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>aging</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bone mineralization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bone resorption</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell maturation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell surface receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>chondrocyte differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>osteoblast development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phospholipase C-activating G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cytosolic calcium ion concentration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of inositol phosphate biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>skeletal system development</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="2">
      <id>BE0004703</id>
      <name>Parathyroid hormone 2 receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>activator</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A17588</ref-id>
            <pubmed-id>10837469</pubmed-id>
            <citation>Jin L, Briggs SL, Chandrasekhar S, Chirgadze NY, Clawson DK, Schevitz RW, Smiley DL, Tashjian AH, Zhang F: Crystal structure of human parathyroid hormone 1-34 at 0.9-A resolution. J Biol Chem. 2000 Sep 1;275(35):27238-44.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P49190" source="Swiss-Prot">
        <name>Parathyroid hormone 2 receptor</name>
        <general-function>Parathyroid hormone receptor activity</general-function>
        <specific-function>This is a specific receptor for parathyroid hormone. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase. PTH2R may be responsible for PTH effects in a number of physiological systems. It may play a significant role in pancreatic function. PTH2R presence in neurons indicates that it may function as a neurotransmitter receptor (By similarity).</specific-function>
        <gene-name>PTH2R</gene-name>
        <locus/>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>146-169
177-196
238-260
276-297
317-337
365-383
395-417</transmembrane-regions>
        <signal-regions>1-24</signal-regions>
        <theoretical-pi/>
        <molecular-weight>62235.335</molecular-weight>
        <chromosome-location>2</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:9609</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>332</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P49190</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PTH2R_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>PTH2 receptor</synonym>
          <synonym>PTHR2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0019615|Parathyroid hormone 2 receptor
MAGLGASLHVWGWLMLGSCLLARAQLDSDGTITIEEQIVLVLKAKVQCELNITAQLQEGE
GNCFPEWDGLICWPRGTVGKISAVPCPPYIYDFNHKGVAFRHCNPNGTWDFMHSLNKTWA
NYSDCLRFLQPDISIGKQEFFERLYVMYTVGYSISFGSLAVAILIIGYFRRLHCTRNYIH
MHLFVSFMLRATSIFVKDRVVHAHIGVKELESLIMQDDPQNSIEATSVDKSQYIGCKIAV
VMFIYFLATNYYWILVEGLYLHNLIFVAFFSDTKYLWGFILIGWGFPAAFVAAWAVARAT
LADARCWELSAGDIKWIYQAPILAAIGLNFILFLNTVRVLATKIWETNAVGHDTRKQYRK
LAKSTLVLVLVFGVHYIVFVCLPHSFTGLGWEIRMHCELFFNSFQGFFVSIIYCYCNGEV
QAEVKKMWSRWNLSVDWKRTPPCGSRRCGSVLTTVTHSTSSQSQVAASTRMVLISGKAAK
IASRQPDSHITLPGYVWSNSEQDCLPHSFHEETKEDSGRQGDDILMEKPSRPMESNPDTE
GCQGETEDVL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0019616|Parathyroid hormone 2 receptor (PTH2R)
ATGCACAGCTTAAATAAAACATGGGCCAATTATTCAGACTGCCTTCGCTTTCTGCAGCCA
GATATCAGCATAGGAAAGCAAGAATTCTTTGAACGCCTCTATGTAATGTATACCGTTGGC
TACTCCATCTCTTTTGGTTCCTTGGCTGTGGCTATTCTCATCATTGGTTACTTCAGACGA
TTGCATTGCACTAGGAACTATATCCACATGCACTTATTTGTGTCTTTCATGCTGAGAGCT
ACAAGCATCTTTGTCAAAGACAGAGTAGTCCATGCTCACATAGGAGTAAAGGAGCTGGAG
TCCCTAATAATGCAGGATGACCCACAAAATTCCATTGAGGCAACTTCTGTGGACAAATCA
CAATATATCGGGTGCAAGATTGCTGTTGTGATGTTTATTTACTTCCTGGCTACAAATTAT
TATTGGATCCTGGTGGAAGGTCTCTACCTGCATAATCTCATCTTTGTGGCTTTCTTTTCG
GACACCAAATACCTGTGGGGCTTCATCTTGATAGGCTGGGGGTTTCCAGCAGCATTTGTT
GCAGCATGGGCTGTGGCACGAGCAACTCTGGCTGATGCGAGGTGCTGGGAACTTAGTGCT
GGAGACATCAAGTGGATTTATCAAGCACCGATCTTAGCAGCTATTGGGCTGAATTTTATT
CTGTTTCTGAATACGGTTAGAGTTCTAGCTACCAAAATCTGGGAGACCAATGCAGTTGGG
CATGACACAAGGAAGCAATACAGGAAACTGGCCAAATCGACACTGGTCCTGGTCCTAGTC
TTTGGAGTGCATTACATCGTGTTCGTATGCCTGCCTCACTCCTTCACTGGGCTCGGGTGG
GAGATCCGCATGCACTGTGAGCTCTTCTTCAACTCCTTTCAGGGTTTCTTTGTGTCTATC
ATCTACTGCTACTGCAATGGAGAGGTTCAGGCAGAGGTGAAGAAGATGTGGAGTCGGTGG
AACCTCTCCGTGGACTGGAAAAGGACACCGCCATGTGGCAGCCGCAGATGCGGCTCAGTG
CTCACCACCGTGACGCACAGCACCAGCAGCCAGTCACAGGTGGCGGCCAGCACACGCATG
GTGCTTATCTCTGGCAAAGCTGCCAAGATCGCCAGCAGACAGCCTGACAGCCACATCACT
TTACCTGGCTATGTCTGGAGTAACTCAGAGCAGGACTGCCTGCCACACTCTTTCCACGAG
GAGACCAAGGAAGATAGTGGGAGGCAGGGAGATGATATTCTAATGGAGAAGCCTTCCAGG
CCTATGGAATCTAACCCAGACACTGAAGGATGCCAAGGAGAAACTGAGGATGTTCTCTGA
</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00002</identifier>
            <name>7tm_2</name>
          </pfam>
          <pfam>
            <identifier>PF02793</identifier>
            <name>HRM</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>parathyroid hormone receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell surface receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>